Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?
- 25 December 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (26) , 3145-3152
Abstract
Classic Hodgkin lymphoma (cHL) is highly curable with risk-adapted first-line treatment. Due to exceptional efficacy, antiprogrammed cell death protein 1 antibodies (aPD1) are increasingly incorporated into first-line treatment. However, the short- and long-term immune-related adverse event burden in this setting is insufficiently understood. Here, we review the currently available evidence on the feasibility and safety of aPD1 first-line cHL treatment. A more harmonized and complete reporting is critical to enable a detailed understanding and comprehensive assessment of aPD1-related morbidity.Keywords
This publication has 44 references indexed in Scilit:
- Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialThe Lancet Oncology, 2025
- Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trialsAnnals of Oncology, 2024
- Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialThe Lancet, 2024
- Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspectiveeClinicalMedicine, 2024
- Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected MelanomaJAMA Network Open, 2023
- Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy – A comprehensive cancer center experienceDiabetes Research and Clinical Practice, 2023
- PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD‐INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.Hematological Oncology, 2023
- Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of lifeEuropean Journal of Cancer, 2022
- Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaAnnals of Oncology, 2021
- Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin LymphomaJAMA Oncology, 2020